 | WEST NILE VIRUS: DETECTION, SURVEILLANCE, AND CONTROL
Copyright © 2001 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 951:1-12 (2001)
© 2001 New York Academy of Sciences
Prospects for Development of a Vaccine against the West Nile Virus
THOMAS P. MONATH
Research and Medical Affairs, Acambis Incorporated, Cambridge Massachusetts 02139, USA
Address for correspondence: Thomas P. Monath, M.D., Vice President, Research and Medical Affairs, Acambis Inc., 38 Sidney Street, Cambridge, MA 02139. Voice: 617-494-1339; fax: 617-494-1741.
tom.monath{at}acambis.com
Vaccination provides the ultimate measure for personal protection against West Nile disease. The development of a West Nile vaccine for humans is justified by the uncertainty surrounding the size and frequency of future epidemics. At least two companies (Acambis Inc. and Baxter/Immuno) have initiated research and development on human vaccines. West Nile encephalitis has also emerged as a significant problem for the equine industry. One major veterinary vaccine manufacturer (Ft. Dodge) is developing formalin-inactivated and naked DNA vaccines. The advantages and disadvantages of formalin-inactivated whole virion vaccines, Japanese encephalitis vaccine for cross-protection, naked DNA, and live attenuated vaccines are described. A novel technology platform for live, attenuated recombinant vaccines (ChimeriVax TM) represents a promising approach for rapid development of a West Nile vaccine. This technology uses yellow fever 17D as a live vector for envelope genes of the West Nile virus. Infectious clone technology is used to replace the genes encoding the prM and E structural proteins of yellow fever 17D vaccine virus with the corresponding genes of West Nile virus. The resulting virion has the protein coat of West Nile, containing all antigenic determinants for neutralization and one or more epitopes for cytotoxic T lymphocytes. The genes encoding the nucleocapsid protein, nonstructural proteins, and untranslated terminal regions responsible for replication remain those of the original yellow fever 17D virus. The chimeric virus replicates in the host like yellow fever 17D but immunizes specifically against West Nile virus.
Key Words: West Nile virus • vaccine • Jennerian vaccine • ChimeriVaxTM platform
This article has been cited by other articles:
|
|
|
|
 
J. Schepp-Berglind, M. Luo, D. Wang, J. A. Wicker, N. U. Raja, B. D. Hoel, D. H. Holman, A. D. T. Barrett, and J. Y. Dong
Complex Adenovirus-Mediated Expression of West Nile Virus C, PreM, E, and NS1 Proteins Induces both Humoral and Cellular Immune Responses
Clin. Vaccine Immunol.,
September 1, 2007;
14(9):
1117 - 1126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. T. BENTLER, J. S. HALL, J. J. ROOT, K. KLENK, B. SCHMIT, B. F. BLACKWELL, P. C. RAMEY, and L. CLARK
SEROLOGIC EVIDENCE OF WEST NILE VIRUS EXPOSURE IN NORTH AMERICAN MESOPREDATORS
Am J Trop Med Hyg,
January 1, 2007;
76(1):
173 - 179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Solomon
Flavivirus Encephalitis
N. Engl. J. Med.,
July 22, 2004;
351(4):
370 - 378.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Charlier, R. Molenkamp, P. Leyssen, J. Paeshuyse, C. Drosten, M. Panning, E. De Clercq, P. J. Bredenbeek, and J. Neyts
Exchanging the Yellow Fever Virus Envelope Proteins with Modoc Virus prM and E Proteins Results in a Chimeric Virus That Is Neuroinvasive in SCID Mice
J. Virol.,
July 15, 2004;
78(14):
7418 - 7426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. W. JOHNSON, T. V. CHAMBERS, M. B. CRABTREE, F. GUIRAKHOO, T. P. MONATH, and B. R. MILLER
ANALYSIS OF THE REPLICATION KINETICS OF THE CHIMERIVAXTM-DEN 1, 2, 3, 4 TETRAVALENT VIRUS MIXTURE IN AEDES AEGYPTI BY REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION
Am J Trop Med Hyg,
January 1, 2004;
70(1):
89 - 97.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Lo, M. Tilgner, and P.-Y. Shi
Potential High-Throughput Assay for Screening Inhibitors of West Nile Virus Replication
J. Virol.,
December 1, 2003;
77(23):
12901 - 12906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Wong, R. H. Boyle, V. L. Demarest, A. N. Woodmansee, L. D. Kramer, H. Li, M. Drebot, R. A. Koski, E. Fikrig, D. A. Martin, et al.
Immunoassay Targeting Nonstructural Protein 5 To Differentiate West Nile Virus Infection from Dengue and St. Louis Encephalitis Virus Infections and from Flavivirus Vaccination
J. Clin. Microbiol.,
September 1, 2003;
41(9):
4217 - 4223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. LANGEVIN, J. ARROYO, T. P. MONATH, and N. KOMAR
HOST-RANGE RESTRICTION OF CHIMERIC YELLOW FEVER-WEST NILE VACCINE IN FISH CROWS (CORVUS OSSIFRAGUS)
Am J Trop Med Hyg,
July 1, 2003;
69(1):
78 - 80.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Bredenbeek, E. A. Kooi, B. Lindenbach, N. Huijkman, C. M. Rice, and W. J. M. Spaan
A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication
J. Gen. Virol.,
May 1, 2003;
84(5):
1261 - 1268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Petersen and A. A. Marfin
West Nile Virus: A Primer for the Clinician
Ann Intern Med,
August 6, 2002;
137(3):
173 - 179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
